← ANALYST RATINGS · TIPRANKS
Codexis (CDXS): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy1 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $7.00, the highest $11.00, the lowest $2.00. The average is +464.5% from the last price of $1.24.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +21.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Hold | +21.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +21.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 | Hold | +21.0% | Upgrade | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +21.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Hold | +21.0% | Reiterated | 01.10.26on TipRanks Sep 30 23:06 | — | |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Reiterated | 22.09.26on TipRanks Sep 23 04:10 | +0.7%next day 0.0% · 5 days −1.7% | ↗ |
| Unknown Analyst | Stephens | $5.00 | Buy | +303.2% | Initiated | 22.09.26on TipRanks 23:05 | 0.0%next day −0.6% · 5 days +1.4% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $9.00 → $8.00−11.1% | Buy | +545.2% | Reiterated | 17.08.26on TipRanks Aug 18 03:55 | +2.4%next day −5.0% · 5 days +5.6% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $11.00 | Buy | +787.1% | Reiterated | 11.08.26on TipRanks Aug 12 10:35 | −1.0%next day +7.9% · 5 days +1.8% | ↗ |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $2.00 | Hold | +61.3% | Reiterated | 11.08.26on TipRanks Aug 12 01:20 | −1.0%next day +7.9% · 5 days +1.8% | ↗ |
| Unknown Analyst | Jefferies | $3.50 | Buy | +182.3% | Assigned | 01.04.26on TipRanks Apr 2 04:25 | +6.0%next day +4.5% · 5 days +34.2% | ↗ |
| Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% | Benchmark Co. | — | Hold | — | Reiterated | 14.11.25on TipRanks 10:15 | +0.9%next day −3.6% · 5 days −4.5% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $5.00 | Buy | +303.2% | Reiterated | 10.11.25on TipRanks 10:00 | +2.0%next day +2.6% · 5 days −8.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Codexis
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.50 at a price of $1.39 (+367.6%); now: $6.50 at $1.24 (+424.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 3 | 2 | 2 |
| Buy | 4 | 2 | 3 | 3 | 3 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.15 to $-0.07). Last quarter: $-0.13.
Sales
Next quarter’s sales estimate — $19M (from $15M to $21M). Last quarter: $15M.
Best top-analyst consensus in the sector · Healthcare
About Codexis
- CEO: Alison Moore
- Employees: 146
- 200 Penobscot Drive, Redwood City, CA, 94063, US
- www.codexis.com
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Data from the stock’s TipRanks forecast page, read 177 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗